Company intelligence / Profile preview

Comanche Biopharma

Concord, Massachusetts, United Statescomanchebiopharma.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Comanche Biopharma has advanced its lead candidate CBP‑4888—a fixed-dose combination of two lipid-conjugated siRNAs targeting sFLT1 mRNA isoforms—into Phase 1 clinical trials for the treatment of preterm preeclampsia. The company received FDA Fast Track designation in August 2023. Clinical results are not yet published; the program remains in early-stage human testing as of early 2024.

Therapeutic areas: Women's Health
Modalities: small interfering RNA (siRNA)oligonucleotides
Industry: Biotech

Drug pipeline

3 assets

CBP-4888

2 more assets in the full pipeline.

Request access →

Partnerships

Collaborations with leading research institutions and pharmaceutical companies are referenced but not specifically named in public sources as of May 2025.

Beyond the preview

Go deeper on Comanche Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Comanche Biopharma.

Explore the full profile